Literature DB >> 15978444

Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases.

Peter J Allen1, Aviram Nissan, Antonio I Picon, Nancy Kemeny, Paul Dudrick, Leah Ben-Porat, Joseph Espat, Alexander Stojadinovic, Alfred M Cohen, Yuman Fong, Philip B Paty.   

Abstract

BACKGROUND: Hepatic arterial infusion pump chemotherapy is an important component in the treatment of patients with hepatic metastases. Successful use of a hepatic arterial infusion pump requires a low technical complication rate. We evaluated the complications and longterm durability of these devices at our institution. STUDY
DESIGN: Between April 1986 and March 2001, 544 patients underwent hepatic arterial infusion pump placement for treatment of unresectable colorectal liver metastases. Patient- and pump-related data were collected by chart review. Pump-related complications, duration of pump function, and overall patient survival were recorded.
RESULTS: Median patient survival was 24 months after pump placement. The incidences of pump failure were 9% at 1 year and 16% at 2 years. Pump complications occurred in 120 (22%) of the patients. Complications that occurred early after operation (< 30 days) were more likely to be salvaged than those occurring late (70% versus 30%, p < 0.001). Increased pump complication rates occurred in the setting of variant arterial anatomy (28% versus 19%, p = 0.02), when the catheter was inserted into a vessel other than the gastroduodenal artery (42% versus 21%, p = 0.004), if the pump was placed during the first half of the study period (1986 to 1993, 25% versus 1994 to 2001, 18%; p = 0.05), and if the surgeon had performed fewer than 25 earlier procedures (< 25, 31% versus > or = 25, 19%; p < 0.002).
CONCLUSIONS: In this large single institution experience, pump-related complications were low, the majority of early pump complications were salvaged, and pump complication rates improved as institutional experience accumulated. Longterm durability of pump function was excellent.

Entities:  

Mesh:

Year:  2005        PMID: 15978444     DOI: 10.1016/j.jamcollsurg.2005.03.019

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  42 in total

1.  Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.

Authors:  Ioannis T Konstantinidis; Bas Groot Koerkamp; Richard K G Do; Mithat Gönen; Yuman Fong; Peter J Allen; Michael I D'Angelica; T Peter Kingham; Ronald P DeMatteo; David S Klimstra; Nancy E Kemeny; William R Jarnagin
Journal:  Cancer       Date:  2015-12-22       Impact factor: 6.860

2.  Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response.

Authors:  Adam C Yopp; Lawrence H Schwartz; Nancy Kemeny; David H Gultekin; Mithat Gönen; Zubin Bamboat; Jinru Shia; Dana Haviland; Michael I D'Angelica; Yuman Fong; Ronald P DeMatteo; Peter J Allen; William R Jarnagin
Journal:  Ann Surg Oncol       Date:  2011-02-01       Impact factor: 5.344

3.  Recent advances and significance of intra-arterial infusion chemotherapy in non-resectable colorectal liver metastasis.

Authors:  Atsushi Nanashima; Hiroaki Takeshita; Takafumi Abo; Kazuo Tou; Kenji Tanaka; Daisuke Fukuda; Masaki Kunizaki; Shigekazu Hidaka; Terumitsu Sawai
Journal:  J Gastrointest Oncol       Date:  2013-06

4.  The Impact of Primary Tumor Location on Long-Term Survival in Patients Undergoing Hepatic Resection for Metastatic Colon Cancer.

Authors:  John M Creasy; Eran Sadot; Bas Groot Koerkamp; Joanne F Chou; Mithat Gonen; Nancy E Kemeny; Leonard B Saltz; Vinod P Balachandran; T Peter Kingham; Ronald P DeMatteo; Peter J Allen; William R Jarnagin; Michael I D'Angelica
Journal:  Ann Surg Oncol       Date:  2017-11-27       Impact factor: 5.344

Review 5.  A systematic review and meta-analysis to reappraise the role of adjuvant hepatic arterial infusion for colorectal cancer liver metastases.

Authors:  Wei Liu; Qing-Kun Song; Bao-Cai Xing
Journal:  Int J Colorectal Dis       Date:  2015-05-27       Impact factor: 2.571

6.  Perioperative Hepatic Arterial Infusion Pump Chemotherapy Is Associated With Longer Survival After Resection of Colorectal Liver Metastases: A Propensity Score Analysis.

Authors:  Bas Groot Koerkamp; Eran Sadot; Nancy E Kemeny; Mithat Gönen; Julie N Leal; Peter J Allen; Andrea Cercek; Ronald P DeMatteo; T Peter Kingham; William R Jarnagin; Michael I D'Angelica
Journal:  J Clin Oncol       Date:  2017-04-20       Impact factor: 44.544

7.  What is the potential role of hepatic arterial infusion chemo-therapy in the current armamentorium against colorectal cancer.

Authors:  Ozkän Kanat; Alexandra Gewirtz; Nancy Kemeny
Journal:  J Gastrointest Oncol       Date:  2012-06

Review 8.  Hepatic arterial infusional chemotherapy in the management of colorectal cancer liver metastases.

Authors:  Alexandre Doussot; Nancy E Kemeny; Michael I D'Angelica
Journal:  Hepat Oncol       Date:  2015-07-27

9.  Hepatic arterial infusion pump chemotherapy for colorectal liver metastases: an old technology in a new era.

Authors:  Y J Ko; P J Karanicolas
Journal:  Curr Oncol       Date:  2014-02       Impact factor: 3.677

10.  Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate?

Authors:  Eran Sadot; Bas Groot Koerkamp; Julie N Leal; Jinru Shia; Mithat Gonen; Peter J Allen; Ronald P DeMatteo; T Peter Kingham; Nancy Kemeny; Leslie H Blumgart; William R Jarnagin; Michael I DʼAngelica
Journal:  Ann Surg       Date:  2015-09       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.